Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 8/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30220585 | 0.88 | NOD2 (0.37) | DGAT1 | |
| SCHEMBL24896363 | 0.84 | SYK (0.42) | CCR9NTRK1MCL1CCR2SYK | |
| SCHEMBL24896371 | 0.77 | GPR35 (0.46) | CCR9MCL1CCR2 | |
| SCHEMBL24896325 | 0.77 | DYRK1A (0.42) | CCR9 | |
| SCHEMBL14565663 | 0.76 | ALDH1A1 (0.55) | NTRK1MCL1CCR2 | |
| SCHEMBL24896337 | 0.76 | MAPT (0.38) | CCR9DGAT1MCL1CCR2 | |
| SCHEMBL24896369 | 0.74 | KDM5A (0.45) | — | |
| SCHEMBL20504453 | 0.73 | MCL1 (0.45) | CCR9MCL1CCR2SYK | |
| SCHEMBL30220602 | 0.71 | GAA (0.42) | SYK | |
| SCHEMBL24896370 | 0.71 | KDM4C (0.40) | CCR9CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4370207-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCR9 3512/4885NTRK1 311/4885DGAT1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.